Merck, Inc.
🇺🇸United States
Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)
Phase 1
Completed
- Conditions
- Ebola Virus
- Interventions
- Biological: V920 VaccineOther: Placebo
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 513
- Registration Number
- NCT02314923
Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)
Phase 1
Completed
- Conditions
- Ebola Viruses
- Interventions
- Biological: V920Other: Placebo
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 39
- Registration Number
- NCT02280408
Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)
Phase 3
Completed
- Conditions
- HIV-1
- Interventions
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 769
- Registration Number
- NCT02275780
A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)
Phase 1
Completed
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Biological: Regular Human Insulin (RHI)Drug: Rescue medicationBiological: Insulin aspart
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 74
- Registration Number
- NCT02269735
Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)
Phase 1
Completed
- Conditions
- Ebola Virus
- Interventions
- Biological: V920Other: Placebo
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 39
- Registration Number
- NCT02269423
Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 13
- Registration Number
- NCT02269059
Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)
Phase 4
Completed
- Conditions
- Pneumococcal Infection
- Interventions
- Biological: PNEUMOVAX™ 23
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 243
- Registration Number
- NCT02260882
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Phase 3
Completed
- Conditions
- Urothelial Cancer
- Interventions
- First Posted Date
- 2014-10-03
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 542
- Registration Number
- NCT02256436
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Phase 2
Completed
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Biological: pembrolizumab
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 172
- Registration Number
- NCT02255097
Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)
Phase 3
Completed
- Conditions
- Hepatitis C
- Interventions
- Drug: PlaceboDrug: Grazoprevir/Elbasvir
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 489
- Registration Number
- NCT02251990
© Copyright 2025. All Rights Reserved by MedPath